A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Saved in:
| Title: | A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. |
|---|---|
| Authors: | Sborov, Douglas W.1 (AUTHOR), Canella, Alessandro2 (AUTHOR), Hade, Erinn M.3 (AUTHOR), Mo, Xiaokui3 (AUTHOR), Khountham, Soun2 (AUTHOR), Wang, Jiang2 (AUTHOR), Ni, Wenjun4 (AUTHOR), Poi, Ming2,4 (AUTHOR), Coss, Christopher2,4 (AUTHOR), Liu, Zhongfa4 (AUTHOR), Phelps, Mitch A.2,4 (AUTHOR), Mortazavi, Amir5 (AUTHOR), Andritsos, Leslie6 (AUTHOR), Baiocchi, Robert A.6 (AUTHOR), Christian, Beth A.6 (AUTHOR), Benson, Don M.6 (AUTHOR), Flynn, Joseph6 (AUTHOR), Porcu, Pierluigi6 (AUTHOR), Byrd, John C.6 (AUTHOR), Pichiorri, Flavia7 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Oct2017, Vol. 58 Issue 10, p2310-2318. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
